Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Xujia Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1607-3867; OpenAlex author ID A5077232584. Sources: OpenAlex.

Their work

Papers
5 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2023: 4 papers · 2024: 1 paper

Papers 5

  1. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.12.008↗
  2. Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two-sample Mendelian randomization analysis of European and East Asian popu… First author DOI 10.1002/cam4.6057↗
  3. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and networ… Co-author DOI 10.1007/s00228-022-03441-9↗
  4. Analysis of Risk Factors for Distant Metastasis of Pancreatic Ductal Adenocarcinoma without Regional Lymph Node Metastasis and a Nomogram Prediction Model for … First author DOI 10.1155/2023/2916974↗
  5. Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. Co-author DOI 10.1177/17588359231186029↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guifang Guo · 5 shared papers, 2023–2024 · strength 0.99
  2. Jinsheng Huang · 4 shared papers, 2023 · strength 0.80
  3. Shengping Li · 3 shared papers, 2023–2024 · strength 0.59
  4. Feng‐Hua Wang · 2 shared papers, 2023–2024 · strength 0.40
  5. Qi Quan · 2 shared papers, 2023–2024 · strength 0.39
  6. Bokang Cui · 1 shared paper, 2023 · strength 0.20
  7. Miao‐Zhen Qiu · 1 shared paper, 2024 · strength 0.20
  8. Yuhong Li · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.